Industry Overview
AI-Based clinical trial solutions for patient matching market was valued at $231.8 million in 2024 and is projected to grow at a CAGR of 27% during the forecast period (2025-2035). The market growth is mainly attributed to increasing demand for precision medicine, growing trial complexity, inefficiencies in traditional recruitment, and regulatory pressure to advance trial diversity and outcomes. AI technologies now empower researchers and CROs to mine real-world data from genomics, EHRs, and registries to classify eligible and diverse participants faster, with better accuracy and inclusivity.
For Full Report Description + Research Methodology + Table of Contents + Infographics @
Regional Outlook
North America holds a major market share
This region captures the major market share in the AI-based clinical trials solution provider market, led by some factors, such as development in healthcare infrastructure, the existence of leading pharmaceutical companies, and heavy investment into AI platforms. The region’s strong healthcare system and technological developments make it a leading hub for clinical trial innovations, including the integration of AI to streamline processes such as data analysis, patient recruitment, and designing trials. For instance, in May 2024, Phesi, a U.S.-based company, enhanced its AI-driven Trial Accelerator platform by presenting the Patient Burden Score. This innovation allows sponsors to better anticipate trial participants’ site visits, procedures, and data documentation needs, improving efficiency and decreasing operational burdens.
Recent Developments
- In November 2024, Bioforum and Medidata took their partnership a step further, providing Bioforum’s clientele in the field of biotechnology with better access to Medidata’s AI-based technologies. Apart from Medidata Rave EDC and RTSM, Bioforum shall employ Medidata Clinical Data Studio and Medidata eConsent to improve data transfer, quality, and regulation of clinical trials.
- In June 2024, EQT declared the acquisition of a majority stake in CluePoints, a leading provider of AI-powered software solutions for Risk-Based Quality Management (RBQM) and data analytics in clinical trials. As developments in technology and data are accelerating healthcare innovation, the markets for RBQM and data interrogation & analytics software are projected to experience strong growth.
- In April 2024, IQVIA partnered with Salesforce to boost the life sciences cloud development for customer engagement for the global life sciences industry. Both companies will bring together technology, talent, and expertise to safeguard a coordinated transition from IQVIA’s OCE to Salesforce’s next-generation life sciences solution.
- In February 2024, Saama declared a newly expanded, multi-year agreement with Pfizer Inc. to scale Smart Data Quality (SDQ), leveraging AI to streamline and boost data review processes across Pfizer’s global clinical research portfolio. The partnership similarly extends further as Pfizer seeks to expedite regulatory submissions using Saama’s innovative biometrics research and analysis information network.
Some of the Key Companies in the AI-Based Clinical Trial Solutions for Patient Matching Market include-
- AiCure, LLC
- Antidote Technologies, Inc.
- Ardigen S.A.
- BioSymetrics
- Clinerion (TriNetX, LLC)
- CliniOps, Inc.
- Consilx
- Deep 6 AI Inc.
- Euretos Services BV
- Exscientia plc
- GNS Healthcare, Inc. (Aitia)
- IBM Corp.
- Innoplexus AG
- Intelegencia
- Koneksa Health Inc.
- Median Technologies
- Phesi, Inc.
- Saama Technologies, LLC.
- Teckro, Inc.
- ai Inc.
- Verily Life Sciences, LLC
AI-Based Clinical Trial Solutions for Patient Matching Market Segmentation Analysis
Global AI-Based Clinical Trial Solutions for Patient Market by Application
- Oncology
- Cardiovascular Diseases
- Neurological Diseases or Conditions
- Metabolic Diseases
- Infectious Diseases
- Others (Gastrointestinal Disorders, and Respiratory Diseases)
Global AI-Based Clinical Trial Solutions for Patient Market by End User
- Pharmaceutical Companies
- Academia
- Others (Contract Research Organizations (CROs), and Government Agencies)
Regional Analysis
- North America
- United States
- Canada
- Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- ASEAN Economies (Singapore, Thailand, Vietnam, Indonesia, and Other)
- Australia and New Zealand
- Rest of Asia-Pacific
- Rest of the World
- Latin America
- Middle East and Africa
Anurag Tiwari
Director Sales Division
+91 780-304-0404
info@omrglobal.com
Visit us on social media:
Facebook | X | LinkedIn